Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
solifenacin + gabapentin
- Development stage
- Unknown
- Lead developer
- Mansoura University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Solifenacin + gabapentin is a combination pharmacological intervention being evaluated for the treatment of non-neurogenic overactive bladder (OAB) in women. The therapy combines solifenacin, a competitive muscarinic M3 receptor antagonist that inhibits detrusor muscle contraction, with gabapentin, a ligand for the α2δ-1 subunit of voltage-gated calcium channels. While gabapentin is primarily used for epilepsy and neuropathic pain, its inclusion in OAB treatment is intended to modulate sensory afferent signaling and reduce bladder hypersensitivity. This dual-mechanism approach aims to provide superior symptom control compared to antimuscarinic monotherapy. The combination has been studied in a Phase 3 randomized controlled trial led by Mansoura University.
- Other names
- solifenacin combined with gabapentinsolifenacin plus gabapentin
02
Targets
M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)
Beyond the preview
Go deeper on solifenacin + gabapentin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on solifenacin + gabapentin.